Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY AI Verdict: PROCEED
Price: $276.32 Analyst target: $279.41 Upside: 1.12%
JNJ is a high-quality, AAA-rated, diversified healthcare leader in a strong uptrend (close 263.86 vs SMA50 238.97 and SMA200 179.79) with ADX 31.8, neutral RSI 59.97, and room below the 281.07 resistance/52w high. Catalysts are pipeline-driven and positive (ESMO prostate cancer data, UK approval of oral psoriasis pill), and insiders show cluster buying (7 buyers, ~$18.8M vs ~$11.8M sold) with news sentiment Somewhat-Bullish (0.21). This is a trend-continuation entry rather than an oversold dip, and the bearish MACD (7.8 < signal 9.73) suggests short-term consolidation.
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
See the full interactive analysis & chart →Informational only — not investment advice.